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AbstraCt
Various studies had been conducted regarding the effect of curcumin on AD patients, thus, many of the 
studies had suggested that curcumin had the potential to prevent and treat AD through several molecular 
mechanisms including act as anti-inflammatory, anti-oxidant, binding the Aβ plaques, metal chelation, and 
lowering cholesterol level. One of the prominent characteristics of this neurodegenerative disease is shown 
by the presence of beta amyloids plaques (Aβ) and inflammation inside the patient’s brains; and as mention 
above curcumin had shown its capabilities in inhibiting the Aβ plaques and act as an anti-inflammation agent. 
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Alzheimer’s diseAse
Alzheimer’s disease (AD) is a neurodegenerative disease and the most common form of dementia. According 
to World Alzheimer Report 2015 9 statistically the dementia prevalence in people aged 60 years and above is estimated 
roughly to range from 10% in North and South America, 8.7% in North Africa and Middle East, 4.6% in Central 
Europe, and 7.6% in Asia. In 2015 a total number of 46.8 million people worldwide are living with dementia with 
AD contribute for 11% of the cases. Alzheimer disease International also speculate by referring to the world trend 
statistics that the number of dementia will almost double every 20 years, it will reach 74.7 million people in 2030, 
and 131.5 million people in 2050. Moreover, the estimated rate of dementia keeps increasing along the time when 
comparing the rate between World Alzheimer Report 2015 and 2009.
AD patient characterized with progressive cognitive deterioration along with declining psychological and 
physical condition such as problems in language, disorientation, mood swings, behavioral issues, and gradual body 
function lost. Moreover, if the disease keeps progressing it will eventually lead to death due to the large amount of 
neurological damage inside the patient’s brain making the body not functional as normal condition 12. 
Currently the particular cause of AD is still unknown, but it is suggested several risk factors that could 
potentially lead to AD including age (60 years above), genetics, head injury, metabolism disease (diabetes, high 
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cholesterol), depression and hypertension 16. Current treatment also not been found yet, but some therapies may 
relief and slowing the progression rate of AD. Although, the specific cause and curing treatment is elusive the study of 
neuropathology of AD had been done in many years and new information still retrieved along with the development 
of medical technologies.
Therefore, scientist tries to find the cure for AD in many ways, from high-tech medical treatment to alternative 
medicine such as herbal. In regards to alternative medicine, scientists had natural compound derived from turmeric 
that may be have the potential to cure AD called curcumin; it is also believed to have many medicinal properties2. 
It is also beneficial in term of natural products, accessibility, and price particularly for patient from middle-low class 
economy.
CurCumin
Curcumin is a bioactive compound derived from a rhizome of a species of plant named Curcuma longa or 
commonly known as turmeric (a native plant from South East Asia region). It was first classified in 1815 by Vogel 
and Pelletier, later on the crystalline form was obtained in 187. For centuries turmeric had been used primarily as a 
food additive in many cuisines including curry, opor, and other spicy dishes; also in Asia it was believed and used as 
a natural herbal remedies to treat common symptoms (fever, inflammation, rash, bug bite, etc.). Currently scientist 
had found that curcumin have a medicinal and other health benefits, thus, varieties of products based on curcumin 
as the main component start to emerge 3.
Nowadays, curcumin commonly found in the form of powder with a bright-yellow color. It was identifying as 
phytopolyphenol, the structure of curcumin is mainly composed of carbon chain linking with two aryl groups. When 
ingested by human, curcumin can distribute inside the blood with a half-life of approximately 8 hours; curcumin 
shown sensitivity towards several factors including visible light, ultraviolet light, high pH level, as well as oxygen 16.
Scientists currently had conducting many research regarding to the curcumin medical properties, it is 
significantly proven to have antioxidant properties which had been shown in the chemical structure of the curcumin 
itself located in the phenolic (OH) groups that attached with the aryl group capable to reducing free radicals such as 
ROS (reactive oxygen species) 8. Therefore, the number of research over curcumin had increase and many of medical 
application of curcumin had been suggested including inhibits cancer cells, metal chelation, and AD treatment.
effeCts of CurCumin on Ad
A various scientific studies have shown the potential of curcumin towards mechanism of Alzheimer’s disease 
treatment. As a neurodegenerative disease AD major infection occur inside the brain, thus, it is important to observe 
the connection between AD and curcumin particularly on the blood-brain-barrier (BBB) which is a highly selective 
semi permeable barrier (allows some molecules such as water, some gases, and lipid soluble molecules by passive 
diffusion) that protects and separates the brain and spinal cord blood circulation from the rest of the body 16. Based 
on research conducted by Ringman and colleagues in 2012 curcumin was shown to have the capabilities to cross 
the BBB membrane due to its hydrophobicity and lipophilic nature. Therefore, it indicates that curcumin medical 
properties can be applied inside the AD patient’s brain.
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InhIbItIon of beta amyloId plaques by CurCumIn
The formations of beta-amyloid (Aβ) plaques along with the presence of neurofibrillary tangle are the one 
of the prominent characteristics shown in AD patient’s brain5. In normal condition, amyloid precursor protein (an 
integral membrane protein) or so called APP is sectioned by multiple enzymes including α-secretase and γ-secretase 
and release p3 peptides which is degrade (the function towards brain is still elusive until now)15. However, in AD the 
APP is cleaved with β-secretase instead of α-secretase, thus, it cleaved on different site by γ-secretase resulting beta-
amyloid (Aβ) d peptide that cannot be regulated. Aβ protein is binding to another Aβ resulting Aβ plaques that can 
trigger neurotoxic effects and capable to degrade brain cells by tau hyper phosphorylation 16. 
Correspond to AD prominent characteristics, currently the development of AD treatment has been targeting 
the Aβ plaques including pharmacological treatments, immunotherapies, and medicinal herbals. From the previous 
studies some substances including ibuprofen and Congo red known to bind to amyloid fibril and shown to reduce 
the accumulation of Aβ plaque; however, both are poor brain penetrant and could cause toxicity given in chronic 
dose 7,8.
Several studies had demonstrated the potential effect of curcumin on the inhibition of Aβ plaques. According 
to the experiment conducted by team of scientists led by Giselle P. Lim in 2001, they observed the effect of high 
(5000 ppm) and low (160 ppm) level dose of curcumin towards APP and Aβ plaques of a mice. The statics shown 
mice given with low dose of curcumin significantly reduce the amount of insoluble Aβ, and soluble Aβ (p3 peptide), 
thus, decreased the plaque burden by 43-50%. Notably, somehow the mice given high dose of curcumin did not show 
significant reduced number; also the levels of APP presence on the membrane were not reduced. Further research 
done by Chi-Fen Lin and colleagues in 2013, had shown similar results regarding the decreasing number of Aβ 
plaques in mice when given with low dose of curcumin (50µM).
CurCumin As Anti-inflAmmAtion And miCrogliAl ACtivAtion
Aside from Aβ plaques, inflammation on the brain also occurs in AD patients. However, this occurrence 
is different with the inflammation in general term, because it does not show fever, swelling, redness, and pain as 
it supposed to be. Therefore, this type of inflammation called neuroinflammation; instead of showing the general 
symptoms it causes damage to neurological functions 13. Neuroinflammation is caused by immune mechanism of 
the microglia cells (macrophage-like cells inside brain) generating constant number of proinflammatory cytokine 
eventually causing neuronal death. Microglia triggers inflammation as well maintaining its function as phagocytes 
that engulf Aβ plaques and repair damaged brain cells 12. Although, in AD the microglia was somehow deceived, thus, 
it activated mostly to proliferate rather than engulf the Aβ plaques 4.
In an experiment conducted by Milan Fiala and team in 2007 on investigating the effect of curcumin towards 
innate immunity response inside the AD patients brain, it was first hypothesized that curcumin may enhance innate 
immune system and increase the clearance of Aβ plaques. They observed the microglia activities through isolated 
macrophage cultures technique combine with the tissue derived from frozen frontal lobe section infected by AD 
to obtain the Aβ plaques; it was incubated and stained by indirect immunofluorescence (conjugate secondary 
antibodies CD68). Then it was added with isolated and purified curcumin inside the macrophage cultures in vitro. 
The experiments shown the curcumin enhance the microglia phagocytosis activity of Aβ plaques in 50% of the 
cases out of 48 samples. Further measurement of the curcumin activity was recorded through phagocytosis assay 
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using fluorescence and confocal microscopy and the sample which added curcumin shown significance activity of 
phagocytosis compare to the control samples 5.
In the 24th Annual Southern California Alzheimer’s Disease Research Conference September 20, 2013; 
Andrea Tenner, Ph.D. stated in her presentation that microglia play an important role in AD it act both induce 
inflammation and phagocytosis the Aβ plaques as mention before; she also stated that the action in microglia could 
actually controlled by several factors, thus it is possible to breakdown each function of the microglia itself and 
regulate the desire microglia activation. Researcher from University of Southern California Los Angeles (UCLA) 
had conducted a study particularly in curcumin inhibition activities of microglial proliferation and differentiation 1 
The observation was done by giving a gradual doses of curcumin (4, 5, 10, 15, 20 µM) on AD mice, after a six-day 
trial it shown that curcumin inhibit the proliferation of microglia cells, by undergo differentiation and maturation 
eventually cell apoptosis. It was also found that curcumin inhibits not only microglia but neuroglia proliferation. 
The inhibition of curcumin seems to be dose dependently; it was observed that the higher curcumin concentration 
given the greater the inhibition. In short, curcumin involves in inhibition of neuroglia proliferation and improving 
the microglia Aβ plaques phagocytosis 11,14.
ConClusion 
Based on the data and discoveries from studies that had mention above, curcumin may become the future 
potent treatment for curing and preventing AD. Particularly in their properties to inhibit the production of Aβ plaques 
in AD patients and enhance the microglia cell activation by reducing the neuroinflammation occur in infected brain. 
However, due to many of the studies and experiment conducted on in vitro and animals based experiments, further 
research had to be conducted to confirm it full function in larger organisms such as human. It also unclears on how 
the drug administration of curcumin can be effective either by taking it directly (orally, intravenous, etc.) or indirectly 
through cuisines (as food additives and spices). But by doing so, a new curcumin based product may be generated 
with the advantages on accessibility, economical achievable, and practical administration to cure neurodegenerative 
disease specifically Alzheimer’s disease.
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